Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Long-Term Investments (2023 - 2026)

Lexaria Bioscience's Long-Term Investments history spans 4 years, with the latest figure at $64014.0 for Q1 2026.

  • Quarterly results put Long-Term Investments at $64014.0 for Q1 2026, changed 0.0% from a year ago — trailing twelve months through Feb 2026 was $64014.0 (changed 0.0% YoY), and the annual figure for FY2025 was $64013.0, up 0.69%.
  • Long-Term Investments for Q1 2026 was $64014.0 at Lexaria Bioscience, roughly flat from $64013.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $64014.0 in Q4 2024 to a low of $48559.0 in Q3 2023.
  • The 4-year median for Long-Term Investments is $64013.5 (2024), against an average of $62027.0.
  • The sharpest move saw Long-Term Investments soared 30.92% in 2024, then decreased 0.0% in 2025.
  • Year by year, Long-Term Investments stood at $48559.0 in 2023, then surged by 31.83% to $64014.0 in 2024, then fell by 0.0% to $64013.0 in 2025, then grew by 0.0% to $64014.0 in 2026.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $64014.0, $64013.0, and $64013.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.